Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIOD-961 is a dry powder (lyophilized) formulation of glucagon developed for use in a proprietary auto-reconstitution device designed to simplify and expedite the emergency treatment of severe hypoglycemia. The product is intended to be mixed with liquid in the device immediately prior to administration, addressing challenges associated with traditional reconstitution procedures during emergencies. Mechanistically, BIOD-961 acts as an agonist at the glucagon receptor (GcGr), stimulating hepatic glucose production through glycogenolysis and gluconeogenesis. In clinical studies, its pharmacokinetic and pharmacodynamic profiles were shown to be bioequivalent to marketed injectable glucagon products such as Eli Lilly's Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BIOD-961.